Streetbeat News

INBX

Inhibrx Biosciences, Inc.

https://inhibrx.com

Industry

Biotechnology

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

Open

14.03

Mkt cap

198M

Volume

74K

High

14.05

P/E Ratio

0.12

52-wk high

18.95

Low

13.52

Div yield

0.06

52-wk low

10.80

Inhibrx (NASDAQ:INBX) reported Q4 2023 GAAP EPS of $(1.73), missing the $(1.04) estimate, but sales of $1.63M exceeded the $50.00K estimate, marking a 496.35% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 2:21 pm

Inhibrx, Inc. (INBX) shares have risen following the announcement of the sale of their asset INBRX-101 to Sanofi for a potential total of $2.2 billion.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 5:06 pm

Sanofi SA (NASDAQ:SNY) is set to acquire Inhibrx Inc's (NASDAQ:INBX) INBRX-101, a therapy for alpha-1 antitrypsin deficiency, for approximately $2.2 billion. The deal includes a merger where Sanofi will buy Inhibrx shares at $30 each, plus a contingent value right of $5 per share, and Inhibrx shareholders will receive one share of the new entity, Inhibrx Biosciences Inc, for every four shares held. Sanofi will also assume Inhibrx's debt and invest $200 million in the new company, retaining an 8% equity interest. The transaction is expected to close in Q2 of 2024. Inhibrx shares rose 2.04% to $34.01, while Sanofi shares fell 0.65% to $50.50 in premarket trading.

Portfolio Pulse from Vandana Singh

January 23, 2024 | 1:00 pm

JMP Securities analyst Reni Benjamin has downgraded Inhibrx (NASDAQ:INBX) from Market Outperform to Market Perform, indicating a change in the firm's outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 9:34 am

Inhibrx, Inc. has agreed to sell its INBRX-101 assets to Sanofi for up to $2.2 billion. Shareholders of Inhibrx will receive $30 per share in cash, a $5 contingent value right (CVR), and 0.25 shares of a new entity, New Inhibrx, which will hold all non-101 assets and liabilities. Sanofi will also pay off Inhibrx's debt and invest $200 million in New Inhibrx. The deal includes the acquisition of INBRX-101, an AAT augmentation therapy, by Sanofi's subsidiary Aventis Inc.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 6:09 am

JMP Securities analyst Reni Benjamin has reiterated a 'Market Outperform' rating on Inhibrx (NASDAQ:INBX) and maintained a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 2:19 pm

The Bear Cave Newsletter has issued a report on Axos Financial (NYSE:AX), raising concerns about the company's culture, loan portfolio, and crypto ventures. Axos, previously known as Bank of Internet, has been criticized by short-sellers for various risks. The report details Axos's history of 'exception-based lending', its ties to high-interest small business lenders, and its relationship with B. Riley (NASDAQ:RILY), whose CEO recently sold stock to meet a margin call. Axos's auditing history is also questioned, with its current and past auditors having limited experience with public companies. The report suggests that Axos's business model may carry risks similar to those that led to the failure of NetBank in 2007.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 3:34 pm

Inhibrx has reported a Q3 earnings per share (EPS) of $(1.10).

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 10:11 pm

Inhibrx, Inc. (NASDAQ:INBX) has announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan and Temozolomide for the treatment of advanced or metastatic, unresectable Ewing sarcoma. The disease control rate was 76.9% among the 13 patients evaluated. The treatment was well tolerated with the most common adverse events being diarrhea, nausea, and fatigue.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:20 pm

Inhibrx has announced that Chiesi Farmaceutici S.p.A has declined to exercise its option for ex-North America rights to develop and commercialise INBRX-101.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 8:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.